Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
RXDX Prometheus Biosciences
106.020-1.320-1.23%
Close
02/08 16:00 ET
High
107.880
Open
107.880
Turnover
39.48M
Low
104.910
Pre Close
107.340
Volume
373.00K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
First Republic Investment Management Inc. Acquires Shares of 5,605 Prometheus Biosciences, Inc. (NASDAQ:RXDX)
First Republic Investment Management Inc. acquired a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) in the third quarter, according to the company in its most recent Form 13F f
Wall Street Analysts Think Prometheus Biosciences, Inc. (RXDX) Could Surge 33.49%: Read This Before Placing a Bet
Prometheus Biosciences (NASDAQ:RXDX) Price Target Raised to $144.00
Prometheus Biosciences (NASDAQ:RXDX – Get Rating) had its price target raised by The Goldman Sachs Group from $117.00 to $144.00 in a report issued on Tuesday, Benzinga reports. The firm presently h
Analyst Expectations for Prometheus Biosciences's Future
Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings23000Last 30D100001M Ago0
Goldman Sachs Adjusts Price Target on Prometheus Biosciences to $144 From $117, Maintains Buy Rating
10:06 AM EST, 01/31/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Prometheus Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/31/2023 25.47% Goldman Sachs $117 → $144 Maintains Buy 12/08/2022 23.73% Credit Suisse $59 → $142 Maint
Goldman Sachs Maintains Buy on Prometheus Biosciences, Raises Price Target to $144
Goldman Sachs analyst Chris Shibutani maintains Prometheus Biosciences (NASDAQ:RXDX) with a Buy and raises the price target from $117 to $144.
Prometheus Biosciences, Inc. (NASDAQ:RXDX) Position Lifted by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC raised its stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) by 197.3% during the third quarter, according to its most recent filin
Investors in Prometheus Biosciences (NASDAQ:RXDX) Have Made a Splendid Return of 262% Over the Past Year
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares in, you can make more than you can lose. For example, the Prometheus Bioscience
Insider Selling: Prometheus Biosciences, Inc. (NASDAQ:RXDX) CEO Sells $2,974,750.00 in Stock
Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) CEO Mark C. Mckenna sold 25,000 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $
Company Overview
More
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .
CEO： Mr. Mark C. McKenna
Market： NASDAQ
Listing Date： 03/12/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet